Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +18.84%
#2 Storj Storj +13.26%
#3 Fake World Assets Fake World Assets +7.59%
#4 OriginTrail OriginTrail +6.03%
#5 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +5.44%
#6 Geodnet Geodnet +5.34%
#7 Collector Crypt Collector Crypt +5.18%
#8 ApeX ApeX +4.55%
#9 OSK OSK +4.40%
#10 Ardor Ardor +4.39%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
NGM Biopharmaceuticals, Inc. NGM Biopharmaceuticals, Inc.

NGM Biopharmaceuticals, Inc.

NGM
Classificação em ações #20909
NGM Biopharmaceuticals, Inc. is a biotechnology company focused on discovering... NGM Biopharmaceuticals, Inc. is a biotechnology company focused on discovering and developing innovative therapies for liver and metabolic ailments, retinal conditions, and various forms of cancer. The company's advanced product candidates include Aldafermin, a modified version of the human hormone fibroblast growth factor 19, which is currently undergoing Phase IIb clinical evaluation for non-alcoholic steatohepatitis (NASH). Another key asset, MK-3655, is an agonistic antibody designed to activate fibroblast growth factor receptor 1c-beta-klotho, also in Phase IIb trials for treating both type 2 diabetes and NASH. NGM's pipeline further encompasses NGM120, an antagonist antibody targeting GFRAL, in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II development for geographic atrophy; and NGM707, a dual antagonist monoclonal antibody (targeting immunoglobulin-like transcript 2/4) in Phase I/II trials for patients with advanced solid tumors. Additionally, the company is developing NGM831 and NGM438, both intended for the treatment of advanced solid tumors. NGM has established significant partnerships, including research, product development, and licensing agreements with Merck Sharp & Dohme Corp. A separate collaboration with Merck & Co., Inc. is dedicated primarily to creating new treatments for pressing unmet patient needs in retinal and cardiovascular-metabolic (CVM) diseases, such as heart failure. Established in 2007, NGM Biopharmaceuticals, Inc. maintains its corporate headquarters in South San Francisco, California.
Preço da ação
$1.54
Última sincronização: 2024-04-08
Valor de mercado
$119.21M
Variação (1 dia)
0.00%
Variação (1 ano)
0.00%
País
US
Negociar NGM Biopharmaceuticals, Inc. (NGM)

Categoria

Healthcare
Histórico de rendimento de dividendos para NGM Biopharmaceuticals, Inc. (NGM)
O rendimento de dividendos (TTM) da NGM Biopharmaceuticals, Inc. (símbolo da ação: NGM) em 2026 é: 0
Rendimento médio dos dividendos nos últimos 5 anos: 0.00%
Histórico de rendimento de dividendos para NGM Biopharmaceuticals, Inc. (NGM) de 2026 a 2026
Rendimento de dividendos no final de cada ano (TTM)
Ano Rendimento de Dividendos Alterar
Não há dados suficientes para as datas fornecidas.
Rendimentos de dividendos (TTM) para empresas semelhantes ou concorrentes
Empresa Rendimento de Dividendos País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
3.12%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH